We use the power of science to deliver needed new medicines to patients
We operate with the long-term outlook required to turn rigorous scientific research into important new medicines. As a result of this focus on R&D, all of our approved medicines were homegrown in our laboratories. Our support for patients extends beyond the lab to disease education and awareness efforts, product support services and our commitment to access and responsible pricing.
Our robust pipeline spans eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.Learn about what's in the pipeline
The Regeneron Genetics Center® aims to impact positive change in our patients’ lives – both in the short term and in the long term.Learn about our approach to patient impact
We are intent on deepening our strong and sustainable portfolio of innovative medicines. We are improving the traditional drug development process through proprietary technologies that accelerate the time from discovery to drug approval and improve the likelihood of success. We are also leading ambitious initiatives, such as the Regeneron Genetics Center®, one of the largest genetics sequencing efforts in the world.EXPLORE OUR TECHNOLOGIES
Understand the annual advancements in our clinical pipeline
We are motivated by the desire to deliver new medicines for people in need – and we want to make sure people can access and afford those medicines regardless of their background or geography. We are committed to developing pricing approaches that facilitate patient access and foster medical innovation through engagement with our stakeholders.
Read page 33 of our 2021 Responsibility Report for our case study on providing access to low- and middle-income countries
Product support programs
We help make our products more accessible through our product support programs. These programs, for example, help healthcare providers and patients navigate health insurance plans and offer co-pay support to eligible commercial patients.
We also provide patient assistance programs that are designed to increase access to medicine and provide education on using medicines safely and appropriately. Our programs help eligible patients throughout their treatment journey with insurance eligibility support, patient resources, financial assistance and access to free medicine.
Compassionate Use: access to investigational medicines
Before a new medicine is widely available to the public, it undergoes rigorous clinical testing to ensure it meets the safety and efficacy criteria required for regulatory approval.
Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials area available. Compassionate Use, also known as expanded access in the U.S., is an approved pathway that, by design, is meant for exceptional circumstances. Our Compassionate Use program has certain established criteria and each request is reviewed by Regeneron’s Compassionate Use Committee.
Patient assistance foundations
We are committed to ensuring that patients can afford and remain compliant with the therapy that best suits their medical needs. We donate to independent third-party charitable foundations, known as Patient Assistance Foundations, which provide financial assistance to patients who might not otherwise be able to afford their medications. Our charitable contributions support patients without regard to the beneficiary’s choice of product, provider, practitioner, supplier or health plan. We provide guidelines and training to our colleagues who might engage with the Foundations, and we review our activities throughout the year to ensure our guidelines are followed.
Increasing disease awareness
We believe patients should be knowledgeable about their disease so they can advocate and make informed decisions around their care. Regeneron supports efforts to empower patients with information to help them better understand and manage their disease. We support organizations that create educational materials and disease management tools for patients and their caregivers. We know that patients are seeking information from the most trusted sources and we want to ensure that there is up-to-date and relevant information wherever they look.
Elevating the patient voice
We recognize that patient advocacy groups represent their respective patient communities’ needs, issues and challenges and can also help to raise awareness, empower patients through education and advocate for patients to receive the best care. We aim to develop meaningful, long-term relationships with patient advocacy groups and to collaborate on addressing important health issues that result in positive patient outcomes.
Supporting patient access
We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health. Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health. Regeneron has supported advocacy training, distribution of access tools, town halls and coalition building for patients and caregivers so that they can have a greater chance for successful outcomes. To submit a request for funding, visit our grants portal.
Read pages 27-29 of our 2021 Responsibility Report to learn how we put our patient advocacy into action.
Hear from the real people impacted by our medicines
We are always looking for ways to make the drug discovery process faster and more efficient, especially in scenarios like the global COVID-19 pandemic where help is desperately needed. To address emerging or rapidly spreading infectious diseases, Regeneron has applied our VelociSuite® technologies and over 30 years of scientific expertise in a ‘rapid response’ manner that parallel tracks certain steps and speeds hand-offs between groups to advance novel antibody treatments as quickly as possible. We’ve been proud to apply our homegrown technologies and novel scientific approach to public health challenges like Ebola, Middle East Respiratory Syndrome (MERS) and COVID-19.
Unfortunately, COVID-19 will not be the last pandemic or epidemic the world faces. This is why we see particular utility in evolving our core technologies, conducting deep biological research and investing in large-scale manufacturing infrastructure for antibody treatments. We are committed to doing what’s right, and we believe applying our resources and expertise to combat dangerous pathogens is crucial to our mission of improving lives through science.
"What can we do to help?"
During the 2014 West African Ebola outbreak, our team was reading increasingly concerning reports and began asking one another, “What can we do to help?” Our eagerness to get involved led to a realization that we could, for the first time, apply our technologies to develop a novel antibody treatment for a deadly viral pathogen, and potentially help address a daunting global health challenge.
We applied our core technologies to generate potent Ebola-neutralizing antibodies at an unprecedented speed and selected a cocktail of three complementary antibodies, condensing a process that normally takes years into less than 12 months. Thankfully, the 2014-2015 Ebola outbreak ended before our investigational compound entered clinical trials, and we instead focused on preclinical and early research to confirm safety in humans. When a new outbreak began in the Democratic Republic of the Congo in 2018, we were ready. We moved quickly to have our investigational medicine made accessible through a compassionate use protocol and included it in an independently run clinical trial to test its safety and efficacy.
Data from this trial ultimately supported the U.S. Food and Drug Administration’s approval of our Ebola antibody cocktail on October 14, 2020.
Moving at pandemic speed
When the novel coronavirus, SARS-CoV-2, began to spread globally in early 2020, our team asked again, “What can we do to help?” Building on prior experience, Regeneron scientists applied the same VelociSuite® technologies in record time. We evaluated antibodies derived from human survivors of COVID-19 as well as our proprietary humanized mouse platforms to rapidly develop a large pool of monoclonal antibody treatment candidates capable of neutralizing the virus. The team selected a highly specific, tightly-binding, non-competing pair of monoclonal antibodies and began exploring the antibody cocktail's potential to be used as a medicine for prophylaxis and treatment of COVID-19. Improving on our prior infectious disease timeline, this combination was ready to enter human clinical trials just five months after the world first learned the SARS-CoV-2 viral sequence.
As part of our rapid response approach and in recognition of the tremendous global need, we simultaneously initiated clinical trials and our large-scale manufacturing process. Manufacturing biologic medicines like monoclonal antibody therapies is a time consuming and precise process, and unfortunately biology can’t be hurried along. Despite the risks and uncertainties, we purposefully began this effort as early as possible so that we would have as many doses as possible immediately available for people around the world.
To further increase access outside of the United States, we also joined forces with Roche to manufacture and deliver our COVID-19 treatment to patients outside of the U.S., significantly increasing global supply. The companies shared a commitment to making the antibody cocktail available to COVID-19 patients around the globe and planned to support access in low- and lower-middle-income countries through drug donations to be made in partnership with public health organizations.
In November 2020, our COVID-19 antibody cocktail was granted an Emergency Use Authorization (EUA) by the FDA, the first combination therapy to receive an EUA and in record time – only ten months after the program's inception. In January 2022, the FDA amended the EUA to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment. Therefore, the treatment is not currently authorized for use in any U.S. states, territories or jurisdictions. Viruses, by their nature, mutate over time leading to variant forms, which means that the activity of antibody treatments may also change or diminish over time. Therefore, we continue to evaluate 'next generation' COVID-19 antibodies in healthy volunteers with the intention of progressing candidates that are safe and effective against currently circulating and future variants.
Nilda’s COVID-19 Journey
Hear one woman’s experience with COVID-19, and how she decided to act quickly following diagnosis to see if treatment was right for her.